Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083278 · ClinicalTrials.gov registry record · Phase 2
Study of MDX-010 in Stage IV Breast Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00083278 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 33 participants.
The verdict
NCT00083278, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This Phase II study is designed to treat patients who have been diagnosed with Stage IV Breast Cancer, which has progressed despite treatment with primary therapies, including hormonal therapy, chemotherapy, and antibody therapy. Thirty-three patients will be treated with the monoclonal antibody MDX-010. The initial antitumor activity profile of MDX-010 will be determined, as well as identification of the induction of any antitumor immunity following the MDX-010 treatment.
Interventions
- DRUG MDX-010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2003-05 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083278
The ClinicalTrials.gov registry entry for NCT00083278 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MDX-010 is the first listed.
NCT00083278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083278 about?
NCT00083278 is a clinical study titled "Study of MDX-010 in Stage IV Breast Cancer". This Phase II study is designed to treat patients who have been diagnosed with Stage IV Breast Cancer, which has progressed despite treatment with primary therapies, including hormonal therapy, chemotherapy, and antibody therapy. Thirty-three patients will be treated with the monoclonal antibody MDX...
What is the current status of trial NCT00083278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2003-05. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00083278?
The interventions under investigation include: MDX-010 (DRUG).
Who is sponsoring clinical trial NCT00083278?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.